FIA
RSLS

FNY Investment Advisers’s ReShape Lifesciences Inc. Common Stock RSLS Stock Holding History

FNY Investment Advisers’s Portfolio RSLS Stock Details RSLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-29
Closed -$9K – 1458
2018
Q2 		$9K Buy
+29
New +$24.8K ﹤0.01% 486

Other funds holding RSLS

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FNY Investment Advisers's RSLS Position: Q3 2018 in Review

FNY Investment Advisers sold out of ReShape Lifesciences Inc. Common Stock (RSLS) in Q3 2018, closing a stake of 29 shares — an estimated $9K sold.

FNY Investment Advisers first reported a position in RSLS in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 15 funds tracked by Wall St. Rank hold RSLS as of Q3 2018.

  • FNY Investment Advisers reported no remaining ReShape Lifesciences Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • FNY Investment Advisers sold 29 ReShape Lifesciences Inc. Common Stock shares in Q3 2018, an estimated $9K.
  • FNY Investment Advisers first reported a position in ReShape Lifesciences Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • FNY Investment Advisers's ReShape Lifesciences Inc. Common Stock position peaked at $9K in Q2 2018.
  • 15 funds tracked by Wall St. Rank held ReShape Lifesciences Inc. Common Stock as of Q3 2018.

Based on FNY Investment Advisers's 13F filing for Q3 2018, filed 29 Oct 2018.